For a vaccine candidate targeting a growth factor relevant for tumor growth is imperative to test not only the specific antibody response elicited against VEGF but also the ability of such antibodies to block the binding of VEGF to VEGFR2 or VEGFR1. The gene discussed is FLT1; the disease is neoplasm.